SC
Scinai Immunotherapeutics Ltd.
SCNI · NASDAQ
$1.69 -0.59% (-$0.01)
1M -50.16%
Market Cap $208.0
P/E Ratio -
Div. Yield -
ROE 26.63%
Bulios Fair Price
$1.85
9.5% upside
Current Price
$1.69
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SCNI is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/S 0.00x
P/B 0.00x
P/E N/A
Growth
-
N/A EPS growth N/A
Rev. growth N/A
FCF growth N/A
Profitability
0 /100
Weak Gross margin 251.95%
Net margin 176.62%
Op. margin 562.79%
Quality
1 /100
Poor ROIC 55.00%
ROE 26.63%
ROA 15.39%
Debt
64 /100
Moderate Debt/Equity 0.31x
Current ratio 1.56x
Int. coverage -25.18x
Stability
1 /100
Unstable Beta 2.08x
EPS volatility 151.55%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SCNI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Amir Reichman
Employees
45
Headquarters
Jerusalem
Upcoming events
02 DEC
Earnings
Upcoming earnings report